Search
Close this search box.

A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer

Primary Sponsor

Victorian Comprehensive Cancer Centre (VCCC)

Collaborating Groups

Trans-Tasman Radiation Oncology Group (TROG)

Accrual Target

32

Trial Chairperson

Dr Steven David, Peter MacCallum Cancer Centre, VIC

Related Post

October 18, 2022

NINJA Radiation Therapy Trial participant tells his journey to treatment

The journey to becoming the 200th participant for the

September 6, 2022

The gift that kept on giving

The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing